Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
13.81
-0.22 (-1.57%)
At close: Mar 11, 2026, 4:00 PM EDT
13.80
-0.01 (-0.07%)
After-hours: Mar 11, 2026, 4:10 PM EDT
Theravance Biopharma Stock Forecast
Stock Price Forecast
The 4 analysts that cover Theravance Biopharma stock have a consensus rating of "Strong Buy" and an average price target of $18.5, which forecasts a 33.96% increase in the stock price over the next year. The lowest target is $14 and the highest is $24.
Price Target: $18.5 (+33.96%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Theravance Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 0 | 0 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $27 → $15 | Strong Buy | Maintains | $27 → $15 | +8.62% | Mar 4, 2026 |
| B. Riley Securities | B. Riley Securities | Strong Buy → Hold Downgrades $28 → $14 | Strong Buy → Hold | Downgrades | $28 → $14 | +1.38% | Mar 4, 2026 |
| BTIG | BTIG | Strong Buy Maintains $40 → $21 | Strong Buy | Maintains | $40 → $21 | +52.06% | Mar 3, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $27 | Strong Buy | Maintains | $20 → $27 | +95.51% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
110.03M
from 64.38M
Increased by 70.90%
Revenue Next Year
102.77M
from 110.03M
Decreased by -6.60%
EPS This Year
1.93
from -1.15
EPS Next Year
0.96
from 1.93
Decreased by -50.18%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 114.0M | 193.5M | ||||
| Avg | 110.0M | 102.8M | ||||
| Low | 105.1M | 80.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 77.1% | 75.9% | ||||
| Avg | 70.9% | -6.6% | ||||
| Low | 63.2% | -27.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.37 | 1.37 | ||||
| Avg | 1.93 | 0.96 | ||||
| Low | 1.37 | 0.19 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | -29.4% | ||||
| Avg | - | -50.2% | ||||
| Low | - | -90.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.